Summit Therapeutics (SMMT) Receivables (2017 - 2022)

Summit Therapeutics (SMMT) has reported Receivables for 6 consecutive years, with $349000.0 the latest figure, recorded in Q4 2022.

• Quarterly Receivables fell 82.88% year-over-year to $349000.0 in Q4 2022, while the trailing twelve-month figure through Dec 2022 was $349000.0 (down 82.88% YoY) and the FY2022 annual result came in at $349000.0, down 82.88% from the prior year.
• Receivables improved to $349000.0 in Q4 2022 per SMMT's latest filing, from $140000.0 in the prior quarter.
• Over the last five years, Receivables for SMMT reached as high as $22.2 million in Q1 2019 and fell as low as $140000.0 in Q3 2022.
• A 5-year average of $6.5 million and a median of $2.2 million in 2021 frame the typical range for Receivables.
• Annual changes were most pronounced in 2018 — Receivables surged 1064.86% — and 2020, when it tumbled 97.15%.
• Year by year, Receivables stood at $19.8 million in 2018, then tumbled by 41.4% to $11.6 million in 2019, then slumped by 97.15% to $331000.0 in 2020, then soared by 515.71% to $2.0 million in 2021, then sank by 82.88% to $349000.0 in 2022.
• According to Business Quant data, Receivables over the past three periods registered $349000.0, $140000.0, and $1.3 million for Q4 2022, Q3 2022, and Q2 2022 respectively.